TIGIT and head and neck squamous cell carcinoma: Collectively, this tripartite evidence establishes TIGIT’s role as an ‘immune sentinel’ in HNSCC neoadjuvant therapy, providing early detection of adaptive resistance dynamics and treatment-responsive exhaustion patterns [99].